Lecture 29: Hereditary Hemorrhagic Telangiectasia and Other Vascular Bleeding Disorders
Hanny Al-Samkari, MD
Presentation Date:
May 14, 2026
HHT is a Multisystem Hereditary Bleeding Disorder with Numerous Morbid and Potentially Fatal Manifestations.
Hanny Al-Samkari, M.D.
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
hal-samkari@mgh.harvard.edu
Disclosures
Dr. Al-Samkari is a member of the Second International HHT Guidelines Committee.
Universal Disclosures (financial):
Consultancy (Agios, Alnylam, Amgen, Alpine, argenx, Sobi, Sanofi, Novartis, Pharmacosmos)
Research Funding (Agios, Sobi, Amgen, Vaderis, Novartis)
Learning Objectives
> Understand the diagnosis and clinical manifestations of hereditary hemorrhagic telangiectasia.
> Properly treat bleeding in hereditary hemorrhagic telangiectasia with antifibrinolytic and antiangiogenic medications.
> Know how to manage iron deficiency and iron deficiency anemia in HHT.
> Recognize other vascular bleeding disorders, including acquired von Willebrand disease.
> About 90% of patients with HHT develop clearly visible telangiectasias on their skin over their lifetime.
> In these examples the telangiectasias are quite plentiful and pronounced but even in less severe cases it is typical for them to be quite obvious on skin examination.
> Image courtesy of Hanny Al-Samkari MD, PhD